"New Drug Class Targeting RAS Oncogenes Being Tested For Myelodysplastic Syndrome"
Premkumar Reddy, PhD, director of experimental cancer therapeutics at the Icahn School of Medicine at Mount Sinai, discusses Rigosertib, a drug he and his colleagues created to target the RAS oncogenes. “The rigosertib mechanism of action represents a new paradigm for attacking the intractable RAS oncogenes,” Dr. Reddy said. Learn more.